A case report of immunotherapy on a patient with advanced gastric cancer by adoptive transfer of OK-432-reactive HLA-matched allogeneic lymphocytes.
Adoptive immunotherapy (AIT) for non-hematological malignancies, using HLA-matched donor lymphocytes, has been rarely reported. For a 35-year-old male patient with peritoneal disseminated advanced gastric cancer, we performed AIT using lymphocytes from his HLA-matched 37-year-old brother and a streptococcal preparation, OK-432, as an antigen. After the donor had been immunized by intradermal administration of OK-432, OK-432-reactive lymphocytes were induced in vitro and transferred to the patient intravenously with OK-432. Low-dose systemic immunochemotherapy, using interleukin-2, 5-fluorouracil and cyclophosphamide, was concurrently administered with AIT. As a result, the Schnitzler metastasis in the patient reduced in size without any significant graft-versus-host-related complications. One of the effector mechanisms of therapeutic benefit was suggested to be cytokine release from the transferred OK-432-reactive lymphocytes. Our findings suggest the safety and efficacy of AIT using lymphocytes from an HLA-matched sibling and OK-432 as an antigen. Further studies to investigate the use of tumor-associated antigen and an HLA-matched sibling's lymphocytes for AIT of advanced cancer are warranted.
Yamagishi
H
H
Second Department of Surgery, Kyoto Prefectural University of Medicine Kawaramachi Hirokoji, Japan.
Ueda
Y
Y
Oka
T
T
D002293:Adenocarcinoma, Scirrhous / Q000276:immunology / Q000628:therapy*; D000328:Adult; D017809:Fatal Outcome; D006650:Histocompatibility Testing; D006801:Humans; D016219:Immunotherapy, Adoptive; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D010844:Picibanil / Q000276:immunology; D013274:Stomach Neoplasms / Q000276:immunology / Q000628:therapy*; D014184:Transplantation, Homologous
D010844:Picibanil